Label: NEOMED PHARMACEUTICAL- hydrocortisone acetate suppository

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated March 5, 2018

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Hydrocortisone acetate suppositories 25mg
    For Rectal Administration
    Rx Only

  • DESCRIPTION:

    Hydrocortisone acetate is a corticosteroid designed chemically as pregn-4-ene 3, 20-dione, 21- (acetyloxy)-11, 17-dihydroxy––(11 β) with the following structural formula:

    structural formula

    Each rectal suppository contains hydrocortisone acetate, USP 25 mg in a specially blended hydrogenated vegetable oil base.

  • CLINICAL PHARMACOLOGY:

    In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.

  • INDICATIONS AND USAGE:

    Hydrocortisone suppositories are indicated for use in:

    • inflamed hemorrhoids
    • post-irradiation (factitial) proctitis
    • as an adjunct in the treatment of chronic ulcerative colitis
    • cryptitis
    • other inflammatory conditions of anorectum and pruritus ani.
  • CONTRAINDICATIONS:

    Hydrocortisone suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

  • PRECAUTIONS:

    Do not use Hydrocortisone suppositories unless adequate proctologic examination is made. If irritation develops, the product should be discontinued and appropriate therapy instituted. In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Hydrocortisone suppository should be discontinued until the infection has been adequately controlled.

    Carcinogenesis:

    No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

    Pregnancy Category C:

    In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women. Hydrocortisone suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.


    It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Hydrocortisone suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

  • ADVERSE REACTIONS:

    The following local adverse reactions have been reported with corticosteroid suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

    To report suspected adverse reactions,
    Contact NEOMED pharmaceutical or www.fda.gov/medwatch

  • DRUG ABUSE AND DEPENDENCE:

    Drug abuse and dependence have not been reported in patients treated with Hydrocortisone suppositories.

  • OVERDOSAGE:

    If signs and symptoms of systemic over dosage occur, discontinue use.

  • DOSAGE AND ADMINISTRATION:

    For Rectal administration.


    OPENING INSTRUCTIONS

    1. Separate plastic film at top opening and pull downward.
    2. Continue pulling downward to almost the full length of the suppository.
    3. Gently remove the suppository from the film pocket

    Opening Instruction

    Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times a day or two suppositories twice daily. In factitial proctitis, the recommended duration of therapy is six to eight weeks or less, according to the response of the individual case.

    All prescription substitutions and/or recommendations using this product shall be made subject to state and federal statutes as applicable.

    PLEASE NOTE: This is not an Orange Book product and has not been subjected to FDA therapeutic or other equivalency testing. No representation is made as to generic status or bio equivalency. Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information provided herein.

  • HOW SUPPLIED:

    Hydrocortisone acetate suppositories 25mg are off-white, smooth surfaced and bullet shaped with one pointed end.

    Box of 12 suppositories, NDC 70898-102-12

  • STORAGE:

    Store at 20º-25ºC (68º-77ºF) [See USP Controlled Room Temperature]. Excursions permitted to 15º- 30ºC (59º-86ºF). Store away from heat. Protect from freezing

  • Other Information

    Manufactured for:
    NEOMED PHARMACEUTICAL
    BRENTWOOD, NY 11717

  • Principal Display Panel

    NDc - 70898-102-12

    NEOMED Phamaceutical

    Hydrocortisone acetate suppositories 25 mg

    Rx Only

    12 Suppositories

    TEMPER EVIDENT:

    Do not use if film is tore or broken

    Label

  • INGREDIENTS AND APPEARANCE
    NEOMED PHARMACEUTICAL 
    hydrocortisone acetate suppository
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:70898-102
    Route of AdministrationRECTAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    HYDROCORTISONE ACETATE (UNII: 3X7931PO74) (HYDROCORTISONE - UNII:WI4X0X7BPJ) HYDROCORTISONE ACETATE25 mg
    Inactive Ingredients
    Ingredient NameStrength
    HYDROGENATED COCO-GLYCERIDES (UNII: XDD37N2GPR)  
    Product Characteristics
    ColorYELLOWScore    
    ShapeBULLETSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:70898-102-1212 in 1 BOX; Type 0: Not a Combination Product03/05/2018
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    UNAPPROVED DRUG OTHER03/05/2018
    Labeler - Neomed Pharmaceutical (048388130)
    Registrant - Neomed Pharmaceutical (048388130)